| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 391.57% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 08/09/2023 | 110.67% | B. Riley Securities | → $15 | Upgrades | Neutral → Buy |
| 05/10/2023 | 391.57% | HC Wainwright & Co. | $110 → $35 | Reiterates | → Buy |
| 03/01/2023 | 40.45% | B. Riley Securities | $29 → $10 | Downgrades | Buy → Neutral |
| 02/13/2023 | 1444.94% | HC Wainwright & Co. | → $110 | Reiterates | → Buy |
| 01/02/2023 | 1444.94% | HC Wainwright & Co. | $207 → $110 | Maintains | Buy |
| 10/14/2022 | 1065.73% | B. Riley Securities | $126 → $83 | Maintains | Buy |
| 09/22/2022 | 279.21% | JP Morgan | $132 → $27 | Downgrades | Neutral → Underweight |
| 08/09/2022 | 1444.94% | Cowen & Co. | $150 → $110 | Maintains | Outperform |
| 06/08/2022 | 2259.55% | Cantor Fitzgerald | $146 → $168 | Maintains | Overweight |
| 05/20/2022 | — | B of A Securities | Initiates Coverage On | → Underperform | |
| 04/26/2022 | 2751.12% | B. Riley Securities | $250 → $203 | Maintains | Buy |
| 03/03/2022 | 2807.3% | HC Wainwright & Co. | $294 → $207 | Maintains | Buy |
| 01/21/2022 | 2006.74% | Cowen & Co. | → $150 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 2835.39% | JP Morgan | $172 → $209 | Maintains | Neutral |
| 06/15/2021 | 3720.22% | Cantor Fitzgerald | $217 → $272 | Maintains | Overweight |
| 05/12/2021 | 2947.75% | Cantor Fitzgerald | $338 → $217 | Maintains | Overweight |
| 05/12/2021 | 4029.21% | HC Wainwright & Co. | $317 → $294 | Maintains | Buy |
| 05/12/2021 | 2161.24% | JP Morgan | $285 → $161 | Downgrades | Overweight → Neutral |
| 03/12/2021 | 4352.25% | HC Wainwright & Co. | $207 → $317 | Maintains | Buy |
| 02/18/2021 | 5475.84% | B. Riley FBR | $334 → $397 | Maintains | Buy |
| 02/05/2021 | 4647.19% | Cantor Fitzgerald | $248 → $338 | Maintains | Overweight |
| 02/01/2021 | 4591.01% | B. Riley FBR | $223 → $334 | Maintains | Buy |
| 12/14/2020 | 2708.99% | Jefferies | → $200 | Initiates Coverage On | → Buy |
| 11/17/2020 | 2807.3% | HC Wainwright & Co. | $290 → $207 | Maintains | Buy |
| 08/06/2020 | 3973.03% | HC Wainwright & Co. | $132 → $290 | Maintains | Buy |
| 08/05/2020 | 1374.72% | Ladenburg Thalmann | → $105 | Downgrades | Neutral → Sell |
| 08/05/2020 | 3762.36% | JP Morgan | $105 → $275 | Upgrades | Neutral → Overweight |
| 08/05/2020 | 3509.55% | B. Riley Securities | $184 → $257 | Maintains | Buy |
| 07/16/2020 | 1753.93% | HC Wainwright & Co. | $101 → $132 | Maintains | Buy |
| 07/08/2020 | 1374.72% | Ladenburg Thalmann | $50 → $105 | Downgrades | Buy → Neutral |
| 06/29/2020 | 1318.54% | HC Wainwright & Co. | $50 → $101 | Maintains | Buy |
| 06/29/2020 | 1388.76% | B. Riley Securities | $74 → $106 | Maintains | Buy |
| 06/19/2020 | 1135.96% | Cantor Fitzgerald | $45 → $88 | Maintains | Overweight |
| 06/05/2020 | 546.07% | JP Morgan | → $46 | Upgrades | Underweight → Neutral |
| 05/28/2020 | 756.74% | B. Riley Securities | $53 → $61 | Maintains | Buy |
| 05/18/2020 | 644.38% | B. Riley Securities | $43 → $53 | Maintains | Buy |
| 05/13/2020 | 532.02% | Cantor Fitzgerald | $23 → $45 | Reiterates | → Overweight |
| 05/12/2020 | 602.25% | HC Wainwright & Co. | $33 → $50 | Reiterates | → Buy |
| 05/12/2020 | 440.73% | Oppenheimer | $19 → $38.5 | Maintains | Outperform |
| 05/12/2020 | 532.02% | Cantor Fitzgerald | $23 → $45 | Maintains | Overweight |
| 05/12/2020 | 503.93% | B. Riley Securities | $29 → $43 | Maintains | Buy |
| 04/30/2020 | 363.48% | HC Wainwright & Co. | $24 → $33 | Reiterates | → Buy |
| 04/24/2020 | 307.3% | B. Riley Securities | $20 → $29 | Maintains | Buy |
| 03/27/2020 | 180.9% | B. Riley Securities | $15 → $20 | Maintains | Buy |
| 03/25/2020 | 237.08% | HC Wainwright & Co. | $17 → $24 | Reiterates | → Buy |
| 03/25/2020 | 223.03% | Cantor Fitzgerald | $16 → $23 | Reiterates | → Overweight |
| 03/17/2020 | 124.72% | Cantor Fitzgerald | $6 → $16 | Upgrades | Neutral → Overweight |
| 02/28/2020 | 124.72% | B. Riley Securities | $12 → $16 | Maintains | Buy |
| 09/24/2019 | 110.67% | Citigroup | $19 → $15 | Maintains | Buy |
| 09/24/2019 | 110.67% | Citigroup | $19 → $15 | Maintains | Buy |
| 09/10/2019 | 82.58% | Oppenheimer | $25 → $13 | Maintains | Outperform |
| 03/04/2019 | -75.42% | B. Riley Securities | $10 → $1.75 | Maintains | Buy |
| 02/28/2019 | — | Piper Sandler | Downgrades | Overweight → Underweight | |
| 02/28/2019 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 01/28/2019 | -15.73% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 12/11/2018 | -43.82% | Oppenheimer | → $4 | Initiates Coverage On | → Outperform |
| 11/26/2018 | — | Piper Sandler | Upgrades | Neutral → Overweight | |
| 09/21/2018 | — | JP Morgan | Upgrades | Underweight → Overweight |
What is the target price for Novavax (NVAX)?
The latest price target for Novavax (NASDAQ: NVAX) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $35.00 expecting NVAX to rise to within 12 months (a possible 391.57% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novavax (NVAX)?
The latest analyst rating for Novavax (NASDAQ: NVAX) was provided by HC Wainwright & Co., and Novavax reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Novavax (NVAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novavax was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating Novavax (NVAX) correct?
While ratings are subjective and will change, the latest Novavax (NVAX) rating was a reiterated with a price target of $0.00 to $35.00. The current price Novavax (NVAX) is trading at is $7.12, which is within the analyst's predicted range.